Lv2
176 积分 2023-12-20 加入
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
1天前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
1天前
已完结
Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer
4天前
已关闭
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
5天前
已完结
Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
5天前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
10天前
已完结
Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape
21天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
27天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
27天前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
27天前
已完结
皖公网安备34019202002308
